Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap | Enterprise Value | Revenue |
|---|
| EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
MR MRNA Moderna, Inc. FY ended Feb 13, 2026 | $137.99 | $55.09B | $54.81B | $1.94B | -$2.76B | -$2.82B | -19.01x | 28.34x | — |
BN BNTX BioNTech SE FY ended Mar 27, 2026 | $102.08 | $25.64B | $20.65B | $2.87B | -$1.12B | -$1.14B | -21.72x | 8.93x | — |
AL ALNY ALNYLAM PHARMACEUTICALS, INC. FY ended Feb 06, 2026 | $237.10 | $31.73B | $33.03B | $3.71B | $499.17M | $313.75M | 101.76x | 8.54x | 46.01x |
SR SRPT Sarepta Therapeutics, Inc. FY ended Feb 24, 2026 | $20.86 | $2.20B | $2.78B | $2.20B | -$686.34M | -$713.41M | -2.93x | 1.00x | — |
NT NTLA Intellia Therapeutics, Inc. FY ended Feb 13, 2026 | $12.87 | $1.80B | $1.46B | $67.67M | -$410.71M | -$412.69M | -3.38x | 26.65x | — |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 46.01x | 1/5 | -$2.75B | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 14.69x | 5/5 | $1.21B | $42.41 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | 10.95x | 5/5 | -$720.07M | — | Target fundamentals do not produce a usable positive equity value. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
MR MRNA Moderna, Inc. FY ended Feb 13, 2026 | $137.99 | $55.09B | $54.81B | $1.94B | -$2.76B | -$2.82B | -19.01x | 28.34x | — |
BN BNTX BioNTech SE FY ended Mar 27, 2026 | $102.08 | $25.64B | $20.65B | $2.87B | -$1.12B | -$1.14B | -21.72x | 8.93x | — |
AL ALNY ALNYLAM PHARMACEUTICALS, INC. FY ended Feb 06, 2026 | $237.10 | $31.73B | $33.03B | $3.71B | $499.17M | $313.75M | 101.76x | 8.54x | 46.01x |
SR SRPT Sarepta Therapeutics, Inc. FY ended Feb 24, 2026 | $20.86 | $2.20B | $2.78B | $2.20B | -$686.34M | -$713.41M | -2.93x | 1.00x | — |
NT NTLA Intellia Therapeutics, Inc. FY ended Feb 13, 2026 | $12.87 | $1.80B | $1.46B | $67.67M | -$410.71M | -$412.69M | -3.38x | 26.65x | — |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVExcluded | Enterprise Multiple | 46.01x | 1/5 | -$2.75B | — | Target fundamentals do not produce a usable positive equity value. |
Price / Sales PSActive | Equity Multiple | 14.69x | 5/5 | $1.21B | $42.41 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | 10.95x | 5/5 | -$720.07M | — | Target fundamentals do not produce a usable positive equity value. |
